July 05, 2024
2 min watch
Save
VIDEO: MRD testing a hot topic in multiple myeloma
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
CHICAGO — In this video, Sandra Mazzoni, DO, discusses the use of minimal residual disease, or MRD, testing in multiple myeloma.
“There’s a lot of hot topics right now in myeloma in general,” Mazzoni, hematologist with the Cleveland Clinic, said.
She highlighted updates using MRD testing as a surrogate marker in clinical trials. The findings were presented at ASCO Annual Meeting.
“I do think those are eventually going to be practice changing cause [sic] right now, there’s really no standardization for MRD testing in multiple myeloma,” Mazzoni said.
Reference:
- Rodriguez-Otero P, et al. Abstract 7502. Presented at: ASCO Annual Meeting; May 31-June 4, 2024; Chicago.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Mazzoni reports consulting for Janssen.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.